Putnam Investments’s Anavex Life Sciences AVXL Stock Holding History

Putnam Investments’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-28,238	Closed	-$490K	–	1180
2021 Q4	$490K	Buy	+28,238	New	+$537K	﹤0.01%	1033

Other funds holding AVXL

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Putnam Investments's AVXL Position: Q1 2022 in Review

Putnam Investments sold out of Anavex Life Sciences (AVXL) in Q1 2022, closing a stake of 28,238 shares — an estimated $490K sold.

Putnam Investments first reported a position in AVXL in Q4 2021 and held it in 1 quarter. The position peaked at $490K in Q4 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

Putnam Investments reported no remaining Anavex Life Sciences position as of Q1 2022 after selling out during the quarter.
Putnam Investments sold 28,238 Anavex Life Sciences shares in Q1 2022, an estimated $490K.
Putnam Investments first reported a position in Anavex Life Sciences in Q4 2021 and held it in 1 quarter.
Putnam Investments's Anavex Life Sciences position peaked at $490K in Q4 2021.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on Putnam Investments's 13F filing for Q1 2022, filed 16 May 2022.